Clinical Trial Update: The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4 [Phase 3]

View source ↗

Summary

The update reports the Phase 3 PRIMO trial evaluating paricalcitol capsules for renal failure–associated cardiac morbidity in CKD stages 3/4; results have been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Left Ventricular Hypertrophy

Drugs mentioned

• Zemplar (Paricalcitol)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Kidney Disease, Left Ventricular Hypertrophy | Phase 3 | Status: COMPLETED | Results posted: 2011-12-23